Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05913687 · ClinicalTrials.gov registry record
Automated Imaging Differentiation of Parkinsonism
A clinical trial of Parkinson Disease and Progressive Supranuclear Palsy, sponsored by University of Florida.
- Active
- Registry status
- 315
- Enrollment target
- 20
- Study locations
NCT05913687: Active study of Parkinson Disease and Progressive Supranuclear Palsy, sponsored by University of Florida.
NCT05913687 is a study of Parkinson Disease and Progressive Supranuclear Palsy that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 315 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05913687, a study of Parkinson Disease and Progressive Supranuclear Palsy, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- 315 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
Primary Outcome
utilizing the automated imaging differentiation of Parkinsonism (AIDP) tool to predict diagnosis compared to the expertise of two movement disorder specialists
Conditions Studied
Interventions
- DIAGNOSTIC_TEST AIDP
Study Locations (20)
California
- University of California San Diego - La Jolla
- University of California San Francisco - San Francisco
Florida
- University of Florida - Gainesville
- University of South Florida - Tampa
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Charlestown
North Carolina
- Duke University Medical Center - Durham
- Wake Forest University - Winston-Salem
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Augusta University - Augusta
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2021-07-22 |
| Est. Completion | 2026-03-31 |
What the registry record for NCT05913687 still lists
NCT05913687 is an observational study that tracks outcomes without assigning an intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which AIDP is the first listed.
NCT05913687 names 20 study sites across 15 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05913687 about?
NCT05913687 is a clinical study titled "Automated Imaging Differentiation of Parkinsonism". The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and ...
What is the current status of trial NCT05913687?
This trial is currently active not recruiting. The enrollment target is 315 participants. The study started on 2021-07-22. Estimated completion is 2026-03-31.
What conditions does trial NCT05913687 study?
This clinical trial studies the following conditions: Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Parkinson Variant.
What interventions are being tested in trial NCT05913687?
The interventions under investigation include: AIDP (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05913687?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05913687 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05913687's enrollment target sits among peer trials
315 33rd of 297 higher than 265 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI